Five-year survival with combined nivolumab and ipilimumab in advanced melanoma

J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.-J. Grob, P. Rutkowski, C.D. Lao, C.L. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P.F. Ferrucci, M. Smylie, D. Hogg, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M.S. CarlinoC. Lebbé, G. McArthur, P.A. Ascierto, G.A. Daniels, G.V. Long, L. Bastholt, J.I. Rizzo, A. Balogh, A. Moshyk, F.S. Hodi, J.D. Wolchok

Research output: Contribution to journalArticle

Original languageItalian
Pages (from-to)1535-1546
Number of pages12
JournalNew England Journal of Medicine
Volume381
Issue number16
DOIs
Publication statusPublished - 2019

Cite this

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., ... Wolchok, J. D. (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 381(16), 1535-1546. https://doi.org/10.1056/NEJMoa1910836